Blood Plasma Derivatives Market by Product Type (Albumin, Anti-inhibitor Coagulation Factor, Factor VIII, Factor IX Concentrate, Immunoglobulins, Rh Immunoglobulin, Alpha 1-Protaese Inhibitor, and Anti–Thrombin), Application (HIV, Hemophilia A, Hemophilia

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,125	258 Pages	Allied Market Research	February, 2022	ALMR17117566

Best Price Guarantee
Price	from $4,125
Length	258 Pages
Publisher	Allied Market Research
Published Date	February, 2022
SKU	ALMR17117566

Blood Plasma Derivatives Market by Product Type (Albumin, Anti-inhibitor Coagulation Factor, Factor VIII, Factor IX Concentrate, Immunoglobulins, Rh Immunoglobulin, Alpha 1-Protaese Inhibitor, and Anti–Thrombin), Application (HIV, Hemophilia A, Hemophilia B, Hepatitis C, Bleeding Disorders, Genetic Lung Disorders, Immune Deficiency System, Liver Conditions, and Viral Disease), and End User (Hospital, Clinic, Transfusion Center, and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030

The global blood plasma derivatives market was valued at $ 36,471.9 million in 2020, and is projected to reach $ 89,767 million by 2030, registering a CAGR of 9.4% from 2021 to 2030.

Blood plasma is liquid component of blood where the blood cells are suspended. It contains dissolved proteins (albumins, globulins, and fibrinogen), clotting factors, hormones, and electrolytes. Plasma maintains the blood pressure and helps in exchange of important minerals such as sodium and potassium to maintain the pH balance in the body. Plasma derivatives are products that are manufactured from human plasma by plasma fractionation techniques. These derivatives include albumin, factor VIII & IX, anti-inhibitor coagulation complex (AICC), and immunoglobulins, including Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III.

The major factor that contributes toward the growth of the blood plasma derivatives market is increase in prevalence of life-threatening diseases such as immunodeficiency disorders and hemophilia. Moreover, other factors that boost the market growth include increase in awareness for blood & plasma donation, rise in geriatric population, and high adoption of blood plasma derivatives products. However, high cost of treatment and risks of side effects associated with the use of plasma derivatives hamper the market growth. Conversely, development of enhanced methods for preservation of plasma derivatives along with advanced procedures for fractionation and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market.

The blood plasma derivatives market is segmented on the basis of type, application, end user, and region. Based on type, the market is fragmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The applications covered in the study include hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand's Disease (vWD), and other applications. By end user, the market is classified into hospitals, clinics, and other end users. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

The report provides an in-depth analysis of the blood plasma derivative market size along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global blood plasma derivative market.

KEY MARKET SEGMENTS

By Type

Albumin
Factor VIII
Factor IX
Immunoglobulin
Hyperimmune Globulin
Others

By Application

Hemophilia
Hypogammaglobulinemia
Immunodeficiency Diseases
Von Willebrand'S Disease
Other Application

By End User

Hospitals
Clinics
Other End Users

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

KEY MARKET PLAYERS

Bayer AG
Biotest AG

CSL limited

Fusion Health Care Pvt. Ltd
Grifols ,S.A
Kedrion Biopharma ,Inc.

LFB S.A

Octapharma AG
Sanofi
Takeda

CHAPTER 1:INTRODUCTION: 1.1.Report Description; 1.2.Key Market Segments; 1.3.Key Benefits; 1.4.Research Methodology; 1.4.1. Primary Research; 1.4.2. Secondary Research; 1.4.3. Analyst Tools and Models
CHAPTER 2:EXECUTIVE SUMMARY: 2.1.CXO Perspective
CHAPTER 3:MARKET LANDSCAPE: 3.1.Market Definition and Scope; 3.2.Key Findings; 3.2.1. Top Investment Pockets; 3.2.2. Top Winning Strategies; 3.3.Porter's Five Forces Analysis; 3.3.1. Bargaining Power of Suppliers; 3.3.2. Threat of New Entrants; 3.3.3. Threat of Substitutes; 3.3.4. Competitive Rivalry; 3.3.5. Bargaining Power among Buyers; 3.4.Market Share Analysis/Top Player Positioning; 3.4.1. Market Share Analysis/Top Player Positioning 2020; 3.5.Market Dynamics; 3.5.1. Drivers; 3.5.2. Restraints; 3.5.3. Opportunities; 3.6.COVID-19 Impact Analysis
CHAPTER 4:BLOOD PLASMA DERIVATIVES MARKET, BY TYPE: 4.1.Market Overview; 4.1.1Market Size and Forecast, By Type; 4.2. Albumin; 4.2.1. Key Market Trends, Growth Factors and Opportunities; 4.2.2. Market Size and Forecast, By Region; 4.2.3. Market Share Analysis, By Country; 4.3. Factor VIII; 4.3.1. Key Market Trends, Growth Factors and Opportunities; 4.3.2. Market Size and Forecast, By Region; 4.3.3. Market Share Analysis, By Country; 4.4. Factor IX; 4.4.1. Key Market Trends, Growth Factors and Opportunities; 4.4.2. Market Size and Forecast, By Region; 4.4.3. Market Share Analysis, By Country; 4.5. Immunoglobulin; 4.5.1. Key Market Trends, Growth Factors and Opportunities; 4.5.2. Market Size and Forecast, By Region; 4.5.3. Market Share Analysis, By Country; 4.6. Hyperimmune Globulin; 4.6.1. Key Market Trends, Growth Factors and Opportunities; 4.6.2. Market Size and Forecast, By Region; 4.6.3. Market Share Analysis, By Country; 4.7. Others; 4.7.1. Key Market Trends, Growth Factors and Opportunities; 4.7.2. Market Size and Forecast, By Region; 4.7.3. Market Share Analysis, By Country
CHAPTER 5:BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION: 5.1.Market Overview; 5.1.1Market Size and Forecast, By Application; 5.2. Hemophilia; 5.2.1. Key Market Trends, Growth Factors and Opportunities; 5.2.2. Market Size and Forecast, By Region; 5.2.3. Market Share Analysis, By Country; 5.3. Hypogammaglobulinemia; 5.3.1. Key Market Trends, Growth Factors and Opportunities; 5.3.2. Market Size and Forecast, By Region; 5.3.3. Market Share Analysis, By Country; 5.4. Immunodeficiency Diseases; 5.4.1. Key Market Trends, Growth Factors and Opportunities; 5.4.2. Market Size and Forecast, By Region; 5.4.3. Market Share Analysis, By Country; 5.5. Von Willebrand'S Disease; 5.5.1. Key Market Trends, Growth Factors and Opportunities; 5.5.2. Market Size and Forecast, By Region; 5.5.3. Market Share Analysis, By Country; 5.6. Other Application; 5.6.1. Key Market Trends, Growth Factors and Opportunities; 5.6.2. Market Size and Forecast, By Region; 5.6.3. Market Share Analysis, By Country
CHAPTER 6:BLOOD PLASMA DERIVATIVES MARKET, BY END USER: 6.1.Market Overview; 6.1.1Market Size and Forecast, By End User; 6.2. Hospitals; 6.2.1. Key Market Trends, Growth Factors and Opportunities; 6.2.2. Market Size and Forecast, By Region; 6.2.3. Market Share Analysis, By Country; 6.3. Clinics; 6.3.1. Key Market Trends, Growth Factors and Opportunities; 6.3.2. Market Size and Forecast, By Region; 6.3.3. Market Share Analysis, By Country; 6.4. Other End Users; 6.4.1. Key Market Trends, Growth Factors and Opportunities; 6.4.2. Market Size and Forecast, By Region; 6.4.3. Market Share Analysis, By Country
CHAPTER 7:BLOOD PLASMA DERIVATIVES MARKET, BY REGION: 7.1.Market Overview; 7.1.1Market Size and Forecast, By Region; 7.2.North America; 7.2.1. Key Market Trends and Opportunities; 7.2.2. Market Size and Forecast, By Type; 7.2.3. Market Size and Forecast, By Application; 7.2.4. Market Size and Forecast, By End User; 7.2.5. Market Size and Forecast, By Country; 7.2.6. United States Blood Plasma Derivatives Market; 7.2.6.1. Market Size and Forecast, By Type; 7.2.6.2. Market Size and Forecast, By Application; 7.2.6.3. Market Size and Forecast, By End User; 7.2.7. Canada Blood Plasma Derivatives Market; 7.2.7.1. Market Size and Forecast, By Type; 7.2.7.2. Market Size and Forecast, By Application; 7.2.7.3. Market Size and Forecast, By End User; 7.2.8. Mexico Blood Plasma Derivatives Market; 7.2.8.1. Market Size and Forecast, By Type; 7.2.8.2. Market Size and Forecast, By Application; 7.2.8.3. Market Size and Forecast, By End User; 7.3.Europe; 7.3.1. Key Market Trends and Opportunities; 7.3.2. Market Size and Forecast, By Type; 7.3.3. Market Size and Forecast, By Application; 7.3.4. Market Size and Forecast, By End User; 7.3.5. Market Size and Forecast, By Country; 7.3.6. Germany Blood Plasma Derivatives Market; 7.3.6.1. Market Size and Forecast, By Type; 7.3.6.2. Market Size and Forecast, By Application; 7.3.6.3. Market Size and Forecast, By End User; 7.3.7. France Blood Plasma Derivatives Market; 7.3.7.1. Market Size and Forecast, By Type; 7.3.7.2. Market Size and Forecast, By Application; 7.3.7.3. Market Size and Forecast, By End User; 7.3.8. U.K Blood Plasma Derivatives Market; 7.3.8.1. Market Size and Forecast, By Type; 7.3.8.2. Market Size and Forecast, By Application; 7.3.8.3. Market Size and Forecast, By End User; 7.3.9. Italy Blood Plasma Derivatives Market; 7.3.9.1. Market Size and Forecast, By Type; 7.3.9.2. Market Size and Forecast, By Application; 7.3.9.3. Market Size and Forecast, By End User; 7.3.10. Spain Blood Plasma Derivatives Market; 7.3.10.1. Market Size and Forecast, By Type; 7.3.10.2. Market Size and Forecast, By Application; 7.3.10.3. Market Size and Forecast, By End User; 7.3.11. Rest Of Europe Blood Plasma Derivatives Market; 7.3.11.1. Market Size and Forecast, By Type; 7.3.11.2. Market Size and Forecast, By Application; 7.3.11.3. Market Size and Forecast, By End User; 7.4.Asia-Pacific; 7.4.1. Key Market Trends and Opportunities; 7.4.2. Market Size and Forecast, By Type; 7.4.3. Market Size and Forecast, By Application; 7.4.4. Market Size and Forecast, By End User; 7.4.5. Market Size and Forecast, By Country; 7.4.6. Japan Blood Plasma Derivatives Market; 7.4.6.1. Market Size and Forecast, By Type; 7.4.6.2. Market Size and Forecast, By Application; 7.4.6.3. Market Size and Forecast, By End User; 7.4.7. China Blood Plasma Derivatives Market; 7.4.7.1. Market Size and Forecast, By Type; 7.4.7.2. Market Size and Forecast, By Application; 7.4.7.3. Market Size and Forecast, By End User; 7.4.8. India Blood Plasma Derivatives Market; 7.4.8.1. Market Size and Forecast, By Type; 7.4.8.2. Market Size and Forecast, By Application; 7.4.8.3. Market Size and Forecast, By End User; 7.4.9. Australia Blood Plasma Derivatives Market; 7.4.9.1. Market Size and Forecast, By Type; 7.4.9.2. Market Size and Forecast, By Application; 7.4.9.3. Market Size and Forecast, By End User; 7.4.10. South Korea Blood Plasma Derivatives Market; 7.4.10.1. Market Size and Forecast, By Type; 7.4.10.2. Market Size and Forecast, By Application; 7.4.10.3. Market Size and Forecast, By End User; 7.4.11. Rest Of Asia-pacific Blood Plasma Derivatives Market; 7.4.11.1. Market Size and Forecast, By Type; 7.4.11.2. Market Size and Forecast, By Application; 7.4.11.3. Market Size and Forecast, By End User; 7.5.LAMEA; 7.5.1. Key Market Trends and Opportunities; 7.5.2. Market Size and Forecast, By Type; 7.5.3. Market Size and Forecast, By Application; 7.5.4. Market Size and Forecast, By End User; 7.5.5. Market Size and Forecast, By Country; 7.5.6. Brazil Blood Plasma Derivatives Market; 7.5.6.1. Market Size and Forecast, By Type; 7.5.6.2. Market Size and Forecast, By Application; 7.5.6.3. Market Size and Forecast, By End User; 7.5.7. South Africa, Blood Plasma Derivatives Market; 7.5.7.1. Market Size and Forecast, By Type; 7.5.7.2. Market Size and Forecast, By Application; 7.5.7.3. Market Size and Forecast, By End User; 7.5.8. Saudi Arabia Blood Plasma Derivatives Market; 7.5.8.1. Market Size and Forecast, By Type; 7.5.8.2. Market Size and Forecast, By Application; 7.5.8.3. Market Size and Forecast, By End User; 7.5.9. Rest of LAMEA Blood Plasma Derivatives Market; 7.5.9.1. Market Size and Forecast, By Type; 7.5.9.2. Market Size and Forecast, By Application; 7.5.9.3. Market Size and Forecast, By End User
CHAPTER 8:COMPANY PROFILES: 8.1. Bayer AG; 8.1.1.Company Overview; 8.1.2.Key Executives; 8.1.3.Company snapshot; 8.1.4.Operating business segments; 8.1.5.Product portfolio; 8.1.6.Business Performance; 8.1.7.Key Strategic Moves and Developments; 8.2. Biotest AG; 8.2.1.Company Overview; 8.2.2.Key Executives; 8.2.3.Company snapshot; 8.2.4.Operating business segments; 8.2.5.Product portfolio; 8.2.6.Business Performance; 8.2.7.Key Strategic Moves and Developments; 8.3. CSL Limited; 8.3.1.Company Overview; 8.3.2.Key Executives; 8.3.3.Company snapshot; 8.3.4.Operating business segments; 8.3.5.Product portfolio; 8.3.6.Business Performance; 8.3.7.Key Strategic Moves and Developments; 8.4. Fusion Health Care Pvt. Ltd; 8.4.1.Company Overview; 8.4.2.Key Executives; 8.4.3.Company snapshot; 8.4.4.Operating business segments; 8.4.5.Product portfolio; 8.4.6.Business Performance; 8.4.7.Key Strategic Moves and Developments; 8.5. Kedrion Biopharma ,Inc.; 8.5.1.Company Overview; 8.5.2.Key Executives; 8.5.3.Company snapshot; 8.5.4.Operating business segments; 8.5.5.Product portfolio; 8.5.6.Business Performance; 8.5.7.Key Strategic Moves and Developments; 8.6. LFB S.A; 8.6.1.Company Overview; 8.6.2.Key Executives; 8.6.3.Company snapshot; 8.6.4.Operating business segments; 8.6.5.Product portfolio; 8.6.6.Business Performance; 8.6.7.Key Strategic Moves and Developments; 8.7. Octapharma AG; 8.7.1.Company Overview; 8.7.2.Key Executives; 8.7.3.Company snapshot; 8.7.4.Operating business segments; 8.7.5.Product portfolio; 8.7.6.Business Performance; 8.7.7.Key Strategic Moves and Developments; 8.8. Takeda; 8.8.1.Company Overview; 8.8.2.Key Executives; 8.8.3.Company snapshot; 8.8.4.Operating business segments; 8.8.5.Product portfolio; 8.8.6.Business Performance; 8.8.7.Key Strategic Moves and Developments; 8.9. Sanofi; 8.9.1.Company Overview; 8.9.2.Key Executives; 8.9.3.Company snapshot; 8.9.4.Operating business segments; 8.9.5.Product portfolio; 8.9.6.Business Performance; 8.9.7.Key Strategic Moves and Developments; 8.10. Grifols; 8.10.1.Company Overview; 8.10.2.Key Executives; 8.10.3.Company snapshot; 8.10.4.Operating business segments; 8.10.5.Product portfolio; 8.10.6.Business Performance; 8.10.7.Key Strategic Moves and Developments
LIST OF TABLES: TABLE 1. GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY TYPE, 2020-2030 ($MILLION); TABLE 2. GLOBAL BLOOD PLASMA DERIVATIVES MARKET FOR ALBUMIN, BY REGION, 2020-2030 ($MILLION); TABLE 3. GLOBAL BLOOD PLASMA DERIVATIVES MARKET FOR FACTOR VIII, BY REGION, 2020-2030 ($MILLION); TABLE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET FOR FACTOR IX, BY REGION, 2020-2030 ($MILLION); TABLE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET FOR IMMUNOGLOBULIN, BY REGION, 2020-2030 ($MILLION); TABLE 6. GLOBAL BLOOD PLASMA DERIVATIVES MARKET FOR HYPERIMMUNE GLOBULIN, BY REGION, 2020-2030 ($MILLION); TABLE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION); TABLE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION, 2020-2030 ($MILLION); TABLE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET FOR HEMOPHILIA, BY REGION, 2020-2030 ($MILLION); TABLE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET FOR HYPOGAMMAGLOBULINEMIA, BY REGION, 2020-2030 ($MILLION); TABLE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET FOR IMMUNODEFICIENCY DISEASES, BY REGION, 2020-2030 ($MILLION); TABLE 12. GLOBAL BLOOD PLASMA DERIVATIVES MARKET FOR VON WILLEBRAND'S DISEASE, BY REGION, 2020-2030 ($MILLION); TABLE 13. GLOBAL BLOOD PLASMA DERIVATIVES MARKET FOR OTHER APPLICATION, BY REGION, 2020-2030 ($MILLION); TABLE 14. GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY END USER, 2020-2030 ($MILLION); TABLE 15. GLOBAL BLOOD PLASMA DERIVATIVES MARKET FOR HOSPITALS, BY REGION, 2020-2030 ($MILLION); TABLE 16. GLOBAL BLOOD PLASMA DERIVATIVES MARKET FOR CLINICS, BY REGION, 2020-2030 ($MILLION); TABLE 17. GLOBAL BLOOD PLASMA DERIVATIVES MARKET FOR OTHER END USERS, BY REGION, 2020-2030 ($MILLION); TABLE 18. GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY REGION, 2020-2030 ($MILLION); TABLE 19. NORTH AMERICA BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 20. NORTH AMERICA BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 21. NORTH AMERICA BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 22. UNITED STATES BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 23. UNITED STATES BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 24. UNITED STATES BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 25. CANADA BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 26. CANADA BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 27. CANADA BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 28. MEXICO BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 29. MEXICO BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 30. MEXICO BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 31. EUROPE BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 32. EUROPE BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 33. EUROPE BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 34. GERMANY BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 35. GERMANY BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 36. GERMANY BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 37. FRANCE BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 38. FRANCE BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 39. FRANCE BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 40. UNITED KINGDOM BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 41. UNITED KINGDOM BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 42. UNITED KINGDOM BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 43. ITALY BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 44. ITALY BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 45. ITALY BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 46. SPAIN BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 47. SPAIN BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 48. SPAIN BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 49. REST OF EUROPE BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 50. REST OF EUROPE BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 51. REST OF EUROPE BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 52. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 53. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 54. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 55. JAPAN BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 56. JAPAN BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 57. JAPAN BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 58. CHINA BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 59. CHINA BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 60. CHINA BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 61. INDIA BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 62. INDIA BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 63. INDIA BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 64. AUSTRALIA BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 65. AUSTRALIA BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 66. AUSTRALIA BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 67. SOUTH KOREA BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 68. SOUTH KOREA BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 69. SOUTH KOREA BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 70. REST OF ASIA-PACIFIC BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 71. REST OF ASIA-PACIFIC BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 72. REST OF ASIA-PACIFIC BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 73. LAMEA BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 74. LAMEA BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 75. LAMEA BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 76. BRAZIL BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 77. BRAZIL BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 78. BRAZIL BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 79. SOUTH AFRICA, BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 80. SOUTH AFRICA, BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 81. SOUTH AFRICA, BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 82. SAUDI ARABIA BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 83. SAUDI ARABIA BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 84. SAUDI ARABIA BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 85. REST OF LAMEA BLOOD PLASMA DERIVATIVES, BY TYPE, 2020-2030 ($MILLION); TABLE 86. REST OF LAMEA BLOOD PLASMA DERIVATIVES, BY APPLICATION, 2020-2030 ($MILLION); TABLE 87. REST OF LAMEA BLOOD PLASMA DERIVATIVES, BY END USER, 2020-2030 ($MILLION); TABLE 88. BAYER AG: KEY EXECUTIVES; TABLE 89. BAYER AG: COMPANY SNAPSHOT; TABLE 90. BAYER AG: OPERATING SEGMENTS; TABLE 91. BAYER AG: PRODUCT PORTFOLIO; TABLE 92. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 93. BIOTEST AG: KEY EXECUTIVES; TABLE 94. BIOTEST AG: COMPANY SNAPSHOT; TABLE 95. BIOTEST AG: OPERATING SEGMENTS; TABLE 96. BIOTEST AG: PRODUCT PORTFOLIO; TABLE 97. BIOTEST AG: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 98. CSL LIMITED: KEY EXECUTIVES; TABLE 99. CSL LIMITED: COMPANY SNAPSHOT; TABLE 100. CSL LIMITED: OPERATING SEGMENTS; TABLE 101. CSL LIMITED: PRODUCT PORTFOLIO; TABLE 102. CSL LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 103. FUSION HEALTH CARE PVT. LTD: KEY EXECUTIVES; TABLE 104. FUSION HEALTH CARE PVT. LTD: COMPANY SNAPSHOT; TABLE 105. FUSION HEALTH CARE PVT. LTD: OPERATING SEGMENTS; TABLE 106. FUSION HEALTH CARE PVT. LTD: PRODUCT PORTFOLIO; TABLE 107. FUSION HEALTH CARE PVT. LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 108. KEDRION BIOPHARMA ,INC.: KEY EXECUTIVES; TABLE 109. KEDRION BIOPHARMA ,INC.: COMPANY SNAPSHOT; TABLE 110. KEDRION BIOPHARMA ,INC.: OPERATING SEGMENTS; TABLE 111. KEDRION BIOPHARMA ,INC.: PRODUCT PORTFOLIO; TABLE 112. KEDRION BIOPHARMA ,INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 113. LFB S.A: KEY EXECUTIVES; TABLE 114. LFB S.A: COMPANY SNAPSHOT; TABLE 115. LFB S.A: OPERATING SEGMENTS; TABLE 116. LFB S.A: PRODUCT PORTFOLIO; TABLE 117. LFB S.A: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 118. OCTAPHARMA AG: KEY EXECUTIVES; TABLE 119. OCTAPHARMA AG: COMPANY SNAPSHOT; TABLE 120. OCTAPHARMA AG: OPERATING SEGMENTS; TABLE 121. OCTAPHARMA AG: PRODUCT PORTFOLIO; TABLE 122. OCTAPHARMA AG: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 123. TAKEDA: KEY EXECUTIVES; TABLE 124. TAKEDA: COMPANY SNAPSHOT; TABLE 125. TAKEDA: OPERATING SEGMENTS; TABLE 126. TAKEDA: PRODUCT PORTFOLIO; TABLE 127. TAKEDA: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 128. SANOFI: KEY EXECUTIVES; TABLE 129. SANOFI: COMPANY SNAPSHOT; TABLE 130. SANOFI: OPERATING SEGMENTS; TABLE 131. SANOFI: PRODUCT PORTFOLIO; TABLE 132. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS; TABLE 133. GRIFOLS: KEY EXECUTIVES; TABLE 134. GRIFOLS: COMPANY SNAPSHOT; TABLE 135. GRIFOLS: OPERATING SEGMENTS; TABLE 136. GRIFOLS: PRODUCT PORTFOLIO; TABLE 137. GRIFOLS: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES: FIGURE 1. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SEGMENTATION; FIGURE 2. GLOBAL BLOOD PLASMA DERIVATIVES MARKET; FIGURE 3. SEGMENTATION BLOOD PLASMA DERIVATIVES MARKET; FIGURE 4. TOP INVESTMENT POCKET IN BLOOD PLASMA DERIVATIVES MARKET; FIGURE 5. TOP WINNING STRATEGIES, 2019-2021*; FIGURE 6. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%); FIGURE 7. TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*; FIGURE 8. MODERATE BARGAINING POWER OF BUYERS; FIGURE 9. MODERATE BARGAINING POWER OF SUPPLIERS; FIGURE 10. MODERATE THREAT OF NEW ENTRANTS; FIGURE 11. LOW THREAT OF SUBSTITUTION; FIGURE 12. HIGH COMPETITIVE RIVALRY; FIGURE 13. TOP PLAYER POSITIONING, 2020; FIGURE 14. MARKET SHARE ANALYSIS, 2020; FIGURE 15. RESTRAINTS AND DRIVERS: BLOOD PLASMA DERIVATIVES MARKET; FIGURE 16. BLOOD PLASMA DERIVATIVES MARKET SEGMENTATION, BY TYPE; FIGURE 17. BLOOD PLASMA DERIVATIVES MARKET FOR ALBUMIN, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 18. BLOOD PLASMA DERIVATIVES MARKET FOR FACTOR VIII, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 19. BLOOD PLASMA DERIVATIVES MARKET FOR FACTOR IX, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 20. BLOOD PLASMA DERIVATIVES MARKET FOR IMMUNOGLOBULIN, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 21. BLOOD PLASMA DERIVATIVES MARKET FOR HYPERIMMUNE GLOBULIN, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 22. BLOOD PLASMA DERIVATIVES MARKET FOR OTHERS, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 23. BLOOD PLASMA DERIVATIVES MARKET SEGMENTATION, BY APPLICATION; FIGURE 24. BLOOD PLASMA DERIVATIVES MARKET FOR HEMOPHILIA, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 25. BLOOD PLASMA DERIVATIVES MARKET FOR HYPOGAMMAGLOBULINEMIA, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 26. BLOOD PLASMA DERIVATIVES MARKET FOR IMMUNODEFICIENCY DISEASES, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 27. BLOOD PLASMA DERIVATIVES MARKET FOR VON WILLEBRAND'S DISEASE, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 28. BLOOD PLASMA DERIVATIVES MARKET FOR OTHER APPLICATION, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 29. BLOOD PLASMA DERIVATIVES MARKET SEGMENTATION, BY END USER; FIGURE 30. BLOOD PLASMA DERIVATIVES MARKET FOR HOSPITALS, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 31. BLOOD PLASMA DERIVATIVES MARKET FOR CLINICS, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 32. BLOOD PLASMA DERIVATIVES MARKET FOR OTHER END USERS, BY COUNTRY, 2020-2030 ($MILLION); FIGURE 33. BAYER AG: NET SALES, 2018-2020 ($MILLION); FIGURE 34. BAYER AG: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 35. BAYER AG: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 36. BIOTEST AG: NET SALES, 2018-2020 ($MILLION); FIGURE 37. BIOTEST AG: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 38. BIOTEST AG: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 39. CSL LIMITED: NET SALES, 2018-2020 ($MILLION); FIGURE 40. CSL LIMITED: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 41. CSL LIMITED: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 42. FUSION HEALTH CARE PVT. LTD: NET SALES, 2018-2020 ($MILLION); FIGURE 43. FUSION HEALTH CARE PVT. LTD: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 44. FUSION HEALTH CARE PVT. LTD: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 45. KEDRION BIOPHARMA ,INC.: NET SALES, 2018-2020 ($MILLION); FIGURE 46. KEDRION BIOPHARMA ,INC.: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 47. KEDRION BIOPHARMA ,INC.: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 48. LFB S.A: NET SALES, 2018-2020 ($MILLION); FIGURE 49. LFB S.A: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 50. LFB S.A: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 51. OCTAPHARMA AG: NET SALES, 2018-2020 ($MILLION); FIGURE 52. OCTAPHARMA AG: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 53. OCTAPHARMA AG: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 54. TAKEDA: NET SALES, 2018-2020 ($MILLION); FIGURE 55. TAKEDA: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 56. TAKEDA: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 57. SANOFI: NET SALES, 2018-2020 ($MILLION); FIGURE 58. SANOFI: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 59. SANOFI: REVENUE SHARE, BY REGION, 2020 (%); FIGURE 60. GRIFOLS: NET SALES, 2018-2020 ($MILLION); FIGURE 61. GRIFOLS: REVENUE SHARE, BY SEGMENT, 2020 (%); FIGURE 62. GRIFOLS: REVENUE SHARE, BY REGION, 2020 (%)